There are currently 80 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, Texas Clinical Research Institute, Llc, Texas Retina Associates and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226
Recruiting
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2025
Locations: Arlington Research Center, Inc., Arlington, Texas
Conditions: Plaque Psoriasis
Register for Updates
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988
Recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/15/2025
Locations: Texas Retina Associates, Arlington, Texas
Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Register for Updates
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743
Recruiting
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: UPNT Research Institute, LLC, Arlington, Texas
Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer
Register for Updates
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993
Recruiting
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/15/2025
Locations: Novartis Investigative Site, Arlington, Texas
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and ol... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Arlington Research Center- Site Number : 8401248, Arlington, Texas
Conditions: Dermatitis Atopic
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Local Institution - 001-888-B, Arlington, Texas +1 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080
Recruiting
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Arlington, TX, Arlington, Texas
Conditions: Diabetic Macular Edema (DME)
Register for Updates
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934
Recruiting
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/03/2025
Locations: Arlington Research Center- Site Number : 8401248, Arlington, Texas
Conditions: Dermatitis Atopic
Register for Updates
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723
Recruiting
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Arlington, Texas
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Know and Own Your Movement-related Metrics Via Wearable Devices
NCT05490641
Recruiting
This study aims to promote daily physical activity in cancer survivors who are at high risk for type 2 diabetes (T2D) by using a personalized biological-based feedback strategy. T2D is one of the most common co-occurring conditions in cancer survivors and can worsen cancer-related health outcomes, especially in those who are insufficiently active. The investigators hypothesize that seeing the immediate impacts of exercise on their biological status will motivate cancer survivors to exercise. The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: The University of Texas at Arlington, Arlington, Texas
Conditions: Cancer, Survivorship
Register for Updates
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
NCT03471117
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatme... Read More
Gender:
ALL
Ages:
Between 35 years and 70 years
Trial Updated:
06/07/2025
Locations: University of Texas at Arlington, Arlington, Texas
Conditions: Chronic Kidney Diseases
Register for Updates
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858
Recruiting
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized myasthenia gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Texas Institute for Neurological Disorders - Arlington, Arlington, Texas
Conditions: Generalized Myasthenia Gravis
Register for Updates